Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage.
We report the efficacy, tolerability and cost of erythocytoapheresis plus recombinant human erythropoietin (rHuEPO) in three patients with severe hereditary hemochromatosis (HH). Results indicate that this regimen could be a valid therapeutic alternative in complicated HH patients. Its cost, however, limits its use to patients whose clinical conditions prevent a proper phlebotomy regimen.
Mariani
Raffaella
R
Pelucchi
Sara
S
Perseghin
Paolo
P
Corengia
Chiara
C
Piperno
Alberto
A
D000328:Adult; D003131:Combined Modality Therapy; D016238:Cytapheresis / Q000191:economics / Q000379:methods*; D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use*; D006432:Hemochromatosis / Q000097:blood / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D006801:Humans; D019190:Iron Overload / Q000209:etiology / Q000628:therapy; D008103:Liver Cirrhosis / Q000209:etiology; D008297:Male; D008565:Membrane Proteins / Q000235:genetics; D008875:Middle Aged; D011994:Recombinant Proteins; D016896:Treatment Outcome
C103673:HFE protein, human; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D008565:Membrane Proteins; D011994:Recombinant Proteins; D004921:Erythropoietin